Campos Mayra Costanti Vilela, Schuler Silvana Simões Velloso, Lacerda Ana Julia, Mazzoni Adriana Cátia, Silva Tamiris, Rosa Francine Cristina Silva, Martins Manoela Domingues, Fernandes Kristianne Porta Santos, Fonseca Elsa Susana, Mesquita-Ferrari Raquel Agnelli, Horliana Anna Carolina Ratto Tempestini, Bussadori Sandra Kalil, Motta Lara Jansiski
Department of Biophotonics Medicine, Nove de Julho University (UNINOVE), Rua Vergueiro, São Paulo, SP, 01525-000, Brazil.
Multidisciplinary Institute of Health, Federal University of Bahia, Vitória da Conquista, State of Bahia, Brazil.
Sci Rep. 2024 Dec 28;14(1):31138. doi: 10.1038/s41598-024-82412-9.
This pragmatic double-blind randomized clinical trial aims to assess the impact of vascular photobiomodulation on post-COVID-19 patients experiencing tension-type headache, orofacial pain, or both persisting for more than 3 months. Participants were divided into two groups: vascular photobiomodulation (VPBM) and simulated VPBM. Their conditions were evaluated using the Brief Pain Inventory (BPI), Visual Analogue Scale, and Headache Impact Test (HIT-6). Data analysis included both inter and intragroup assessments, employing per-protocol and intention-to-treat analyses. Significant differences were observed in pain levels pre- and post-treatment and between the two groups. These differences were evident in the average pain experienced in the previous week (p = 0.010) and various dimensions of the BPI questionnaire, such as the degree of pain interference with walking (p = 0.011), work (p = 0.009), sleep (p = 0.012), and enjoyment of life (p = 0.016). However, there was no statistically significant difference in headache impact on activities of daily living as measured by the HIT. Vascular photobiomodulation shows promise in reducing pain and enhancing the ability to engage in daily activities among post-COVID-19 patients experiencing persistent headaches and orofacial pain.
这项实用的双盲随机临床试验旨在评估血管光生物调节对患有紧张型头痛、口面部疼痛或两者持续超过3个月的新冠后患者的影响。参与者被分为两组：血管光生物调节（VPBM）组和模拟VPBM组。使用简明疼痛量表（BPI）、视觉模拟量表和头痛影响测试（HIT-6）对他们的状况进行评估。数据分析包括组间和组内评估，采用符合方案分析和意向性分析。在治疗前后的疼痛水平以及两组之间观察到了显著差异。这些差异在前一周的平均疼痛（p = 0.010）以及BPI问卷的各个维度中很明显，例如疼痛对行走（p = 0.011）、工作（p = 0.009）、睡眠（p = 0.012）和生活乐趣（p = 0.016）的干扰程度。然而，通过HIT测量，头痛对日常生活活动的影响没有统计学上的显著差异。血管光生物调节在减轻患有持续性头痛和口面部疼痛的新冠后患者的疼痛以及增强其参与日常活动的能力方面显示出前景。
